Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
AOL6d
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
This approach allows Absci to quickly advance and monetize clinical-stage assets, aligning well with its AI/ML-driven platform. Price Action: ABSI stock is up 23% at $3.96 at the last check on ...
Benzinga.com6d
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...
The Business Journals6d
Absci shares jump as analyst lauds 'practical' AI drug company
The company recently got a $20 million boost, an investment from chipmaker and Intel rival AMD. Absci went public in late July 2021 and its market cap rose to around $2.5 billion as shares nudged ...
AMD stock touches 52-week low at $114.41 amid market shifts
Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has reached a 52-week low, dipping to $114.41, as investors navigate a challenging market environment. According to InvestingPro data, the company ...
Investing6d
Needham initiates Absci shares with Buy rating on strategy
Absci's recent strategic collaborations with Advanced Micro Devices (NASDAQ:AMD) and AstraZeneca (NASDAQ:AZN) were also spotlighted. The partnership with AMD, which includes a $20 million ...
Investing6d
Needham initiates Absci shares with Buy rating on strategy
Absci's recent strategic collaborations with Advanced Micro Devices (NASDAQ:AMD) and AstraZeneca (NASDAQ:AZN) were also spotlighted. The partnership with AMD, which includes a $20 million investment, ...